Regeneron signs Mammoth gene editing deal worth $100M upfront Fierce Biotech - 25 Apr 2024 Regeneron signs Mammoth gene editing deal worth $100M upfront ... More
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery BioSpace - 25 Apr 2024 Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery ... More
Regeneron inks $100M deal to develop gene-editing therapies Crain's New York Business - 26 Apr 2024 Regeneron inks $100M deal to develop gene-editing therapies ... More
Regeneron (REGN) Reports Next Week: What You Should Expect Yahoo Finance - 25 Apr 2024 Regeneron (REGN) Reports Next Week: What You Should Expect ... More
Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent FiercePharma - 26 Apr 2024 Head-to-head, it's AbbVie's Rinvoq over Regeneron's Dupixent ... More
Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines MedCity News - 25 Apr 2024 Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines ... More
Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration Genetic Engineering & Biotechnology News - 25 Apr 2024 Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration ... More
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study Reuters.com - 25 Apr 2024 AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study ... More
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors MarketWatch - 26 Apr 2024 Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors ... More
Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct) Bloomberg Law - 26 Apr 2024 Regeneron Fails to Quash Skin Cancer Drug Warning Suit (Correct) ... More
Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth Reuters.com - 25 Apr 2024 Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth ... More
Sales of Roche's juggernaut Vabysmo rout the analyst consensus FiercePharma - 24 Apr 2024 Sales of Roche's juggernaut Vabysmo rout the analyst consensus ... More
Regeneron and Mammoth team up to develop gene editing therapies Pharmaceutical Technology - 26 Apr 2024 Regeneron and Mammoth team up to develop gene editing therapies ... More
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks Yahoo Finance - 24 Apr 2024 Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks ... More
Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch Investopedia - 11 Apr 2024 Regeneron Stock Under Microscope After DOJ Price Reporting Complaint—Key Levels to Watch ... More
US Intensifies Drug Discount Debate in Latest Regeneron Lawsuit Bloomberg Law - 12 Apr 2024 US Intensifies Drug Discount Debate in Latest Regeneron Lawsuit ... More
Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech BioSpace - 15 Apr 2024 Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech ... More
Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond Fierce Biotech - 15 Apr 2024 Regeneron builds new venture arm with $500M commitment to invest in biotech and beyond ... More
Regeneron to defend against DOJ complaint on drug-price manipulation Reuters.com - 15 Apr 2024 Regeneron to defend against DOJ complaint on drug-price manipulation ... More